Form 4: Mitchell Glass Receives 50,000 Options in Q/C Tech

Chief Medical Officer Mitchell Glass was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.

Summary

• Mitchell Glass, Chief Medical Officer of Q/C Technologies, Inc., acquired 50,000 employee stock options.
• The options have an exercise price of $5.00 per share.
• The grant date is April 13, 2026, with an expiration date of April 13, 2036.
• The options are fully exercisable as of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of interests between the Chief Medical Officer and shareholders through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The options are subject to forfeiture if the Reporting Person ceases to be employed by or provide services to the Issuer.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity compensation grant.

Management Comments

• No specific management commentary was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives are standard practice in the technology and biotech sectors to incentivize long-term performance and retention.

Comparison to Industry Standards

• The grant of stock options to a Chief Medical Officer is consistent with standard executive compensation packages in the technology and life sciences industries.
• The 10-year term for the options is a standard industry practice for employee stock option plans.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• The reporting person may choose to exercise these options in the future, subject to the terms of the company's equity incentive plan.

Key Dates

Keywords

QCLS, Q/C Technologies, Form 4, Insider Trading, Stock Options, Chief Medical Officer